WO2005039586A1 - Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders - Google Patents
Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders Download PDFInfo
- Publication number
- WO2005039586A1 WO2005039586A1 PCT/EP2004/012080 EP2004012080W WO2005039586A1 WO 2005039586 A1 WO2005039586 A1 WO 2005039586A1 EP 2004012080 W EP2004012080 W EP 2004012080W WO 2005039586 A1 WO2005039586 A1 WO 2005039586A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- amino
- pyridinyl
- pyrimidinyl
- benzamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *c(c(Nc1nccc(-c2cccnc2)n1)c1)ccc1C(N(*)*)=O Chemical compound *c(c(Nc1nccc(-c2cccnc2)n1)c1)ccc1C(N(*)*)=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the invention relates also to possible tautomers of the compounds of formula
- Substituted alkyl is alkyl as last defined, especially lower alkyl, preferably methyl; where one or more, especially up to three, substituents may be present, primarily from the group selected from halogen, especially fluorine, amino, N-lower alkylamino, N,N-di-lower alkylamino, N-lower alkanoylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, and phenyl-lower alkoxycarbonyl. Trifluoromethyl is especially preferred.
- the invention further relates to the use of COMPOUND or a N-Oxide or a pharmaceutically acceptable salt thereof for the manufacture of medicament having an activity on protein kinases VEGFR-2, Tie-2, c-Src, c-Met, FGFR-1 , Flt-1 , HER-2, c-Abl, c-Raf, PDGFR-beta, c- Kit, or on a combination of the above enzymes, for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation and/or aggregation such as neurodegenerative diseases like Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis.
- neurodegenerative diseases like Alzheimer's disease, Down's Syndrome, memory and cognitive impairment
- dementia amyloid neuropathies
- brain inflammation nerve and brain trauma
- vascular amyloidosis
- HEK APPswe cells are plated in microtiter plates precoated with 10 ⁇ g/ml poly-D-lysine at 12O00 cells/well in 100 ⁇ l/well DMEM medium supplemented with 10% FCS, 0.25 mg/ml G418 sulfate, 1% penicillin streptomycin. The following day, supernatant is replaced with 90 ⁇ l/well of fresh medium and 10 ⁇ l/well of compound diluted in culture medium are added. Two types of control wells are used: cell culture medium without cells plus 10 ⁇ l/well of all compound dilutions (background signals) and cell culture medium from untreated cells (positive control). 24 hours later after compound addition, conditioned medium is collected and A ⁇ levels determined by a specific sandwich ELISA.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the use of an inhibitor of formula (I) or a N-Oxide or a pharmaceutically acceptable salt thereof having an activity on protein kinases VEGFR-2, Tie-2, c-Src, c-Met, FGFR-1, Flt-1, HER-2, c-Abl, c-Raf, PDGFR-beta, c-Kit, or on a combination of the above enzymes, for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation and/or aggregation such as neurodegenerative diseases like Alzheimer’s disease, Down’s Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis.
Description
Pyridinyl-pyrimidinylamino-benzamide derivatives
The invention relates to the use of compounds (hereinafter: "COMPOUND ") or a N-Oxide or a pharmaceutically acceptable salt thereof having an activity on protein kinases VEGFR-2, Tie-2, c-Src, c-Met, FGFR-1 , Flt-1 , HER-2, c-Abl, c-Raf, PDGFR-beta, c-Kit, or on a combination of the above enzymes, for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation and/or aggregation such as neurodegenerative diseases like Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis.
COMPOUND is preferably a compound of formula I
R represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, carboxy- lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl;
R2 represents hydrogen, lower alkyl, optionally substituted by one or more identical or different radicals R3, cycloalkyl, benzcycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted; and R3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amino, mono- or disubstituted amino,. cycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two
or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted;
or wherein R and R2 together represent alkylene with four, five or six carbon atoms optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, oxo, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms; oxaalkylene with one oxygen and three or four carbon atoms; or azaalkylene with one nitrogen and three or four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy-lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N- disubstituted carbamoyl-lower alkyl, cycloalkyl, lower alkoxycarbonyl, carboxy, phenyl, substituted phenyl, pyridinyl, pyrimidinyl, or pyrazinyl;
R represents hydrogen, lower alkyl, or halogen;
Or more preferably COMPOUND is a compound selected from
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyhdinyl)-2-pyrimidinyl]amino]benzanilide,
4-Methyl-Λ/-(3-pyridinyl)-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide,
/S/-(4-Chlorophenyl)-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide,
2(R)- and 2(S)-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoylamino]propanoic acid,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(8-quinolinyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(3-[trifluoromethoxy]phenyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(2-pyrrolidinoethyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(3-pyrrolidinophenyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(1-[2-pyrimidinyl]-4-piperidinyl)benzamide,
Λ/-(4-Di-[2-methoxyethyl]amino-3-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
Λ/-(4-[1 H-lmidazolyl]-3-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(2-pyrrolidino-5- trifluoromethylphenyl)benzamide,
Λ/-(3,4-difluorophenyl)-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(3-trifluoromethylbenzyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(3-trifluoromethylphenyl)benzamide,
Λ/-(3-Chloro-5-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
Λ/-(4-Dimethylaminobutyl)-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide,
4-Methyl-Λ/-[4-(4-methyl-1-piperazinyl)-3-trifluoromethylphenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(2,2,2-trifluoroethoxy)-3- trifluoromethylphenyljbenzamide,
4-Methyl-Λ/-[4-(2-methyl-1 H-imidazolyl)-3-trifluoromethylphenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-Λ/-(4-phenyl-3-trifluoromethylphenyl)-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-Λ/-[4-(4-methyl-1 H-imidazolyl)-3-trifluoromethylphenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
Methyl 2(R)- and 2(S)-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoylamio]-3-[4- hydroxyphenyl]propanoate,
Λ/-[2-(/V-Cyclohexyl-Λ/-methylaminomethyl)phenyl]-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
Λ/-[3-[2-(1H-lmidazolyl)ethoxy]phenyl]-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-Λ/-[3-morpholino-5-trifluoromethylphenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(4-pyrrolidino-3- trifluoromethylphenyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(4-piperidino-3- trifluoromethylphenyl)benzamide,
4-Methyl-Λ/-[4-morpholino-3-trifluoromethylphenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
/V-(4-Ethylamino-3-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(3-trifluoromethoxyphenyl)benzamide,
Λ/-[4-(2-Hydroxypropylamino)-3-trifluoromethylphenyl]-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
Λ/-(4-Diethylamino-3-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[3-(3-pyridinyl)-5- trifluorophenyl]benzamide,
Λ/-[3-[3-(1 H-lmidazolyl)propoxy]phenyl]-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(3-pyridinyl)-3- trifluorophenyljbenzamide,
4-Methyl-/V-[3-(4-methyl-1-piperazinyl)-5-trifluorophenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-Λ/-[3-methylcarbamoyl-5-trifluorophenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-Λ/-[3-methylcarbamoyl-5-morpholino]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide.
Further compounds which are even more particularly preferred are:
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[3-[3-(1H-imidazol-1-yl)propoxy]- phenyljbenzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[3-[2-(1 H-imidazol-1- yl)ethoxy]phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(ethylamino)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(diethylamino)-3-
(trifluoromethyl)phenyl]benzamide,
(±)-4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-[(2-hydroxypropyl)amino]-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-[bis(2-methoxyethyl)amino]-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(4-methyl-1-piperazinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(1-piperidinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[4-(1-pyrrolidinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyI)-2-pyrimidinyl]amino]-Λ/-[4-(4-morpholinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-phenyl-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[3-[4-(3-pyridinyl)-3-
(trifluoromethyl)phenyl]methyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyhmidinyl]amino]-/V-[4-(1 H-imidazol-1-yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(2,4-dimethyl-1 H-imidazol-1-yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(4-methyl-1 H-imidazol-1-yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(2-methyl-1 H-imidazol-1-yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-/V-[3-(4-morpholinyl)-5-
[(methylamino)carbonyl]phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-/V-[3-[(methylamino)carbonyl]-5-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[5-(3-pyridinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-/V-[5-(4-morpholinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[5-(2-methyl-1 H-imidazol-1-yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2- ylamino)-benzamide ,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[5-(5-methyl-1H-imidazol-1-yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-/V-[3-(4-methyl-1-piperazinyl)-5-
(trifluoromethyl)phenyl]benzamide, and
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[2-(1-pyrrolidinyl)-5-
(trifluoromethyl)phenyl]benzamide.
or most preferably COMPOUND is 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide having the formula I
Compounds of formula I and methods for the preparation of such compounds are in particular generically and specifically disclosed in the patents and patent application PCT/EP03/07198, in particular in the compound claims and the final products of the working examples, the subject-matter of the final products, the pharmaceutical preparations and the claims is hereby incorporated into the present application by reference to this publication.
The general terms used hereinbefore and hereinafter preferably have within the context of this disclosure the following meanings, unless otherwise indicated:
The prefix "lower" denotes a radical having up to and including a maximum of 7, especially up to and including a maximum of 4 carbon atoms, the radicals in question being either linear or branched with single or multiple branching.
Where the plural form is used for compounds, salts, and the like, this is taken to mean also a single compound, salt, or the like.
Any asymmetric carbon atoms may be present in the (R)-, (S)- or (R,S)-configuration, preferably in the (R)- or (S)-configuration. The compounds may thus be present as mixtures
of isomers or as pure isomers, preferably as enantiomer-pure diastereomers.
The invention relates also to possible tautomers of the compounds of formula
Lower alkyl is preferably alkyl with from and including 1 up to and including 7, preferably from and including 1 to and including 4, and is linear or branched; preferably, lower alkyl is butyl, such as n-butyl, sec-butyl, isobutyl, tert-butyl, propyl, such as n-propyl or isopropyl, ethyl or methyl. Preferably lower alkyl is methyl, propyl or tert-butyl.
Lower acyl is preferably formyl or lower alkylcarbonyl, in particular acetyl.
An aryl group is an aromatic radical which is bound to the molecule via a bond located at an aromatic ring carbon atom of the radical. In a preferred embodiment, aryl is an aromatic radical having 6 to 14 carbon atoms, especially phenyl, naphthyl, tetrahydronaphthyl, fluorenyl or phenanthrenyl, and is unsubstituted or substituted by one or more, preferably up to three, especially one or two substituents, especially selected from amino, mono- or disubstituted amino, halogen, lower alkyl, substituted lower alkyl, lower alkenyl, lower alkynyl, phenyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, benzoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, ureido, mercapto, sulfo, lower alkylthio, phenylthio, phenyl-lower alkylthio, lower alkylphenylthio, lower alkylsulfinyl, phenylsulfinyl, phenyl-lower alkylsulfinyl, lower alkylphenylsulfinyl, lower alkylsulfonyl, phenylsulfonyl, phenyl-lower alkylsulfonyl, lower alkylphenylsulfonyl, halogen-lower alkylmercapto, halogen-lower alkylsulfonyl, such as especially trifluoromethanesulfonyl, dihydroxybora (-B(OH)2), heterocyclyl, a mono- or bicyclic heteroaryl group and lower alkylene dioxy bound at adjacent C-atoms of the ring, such as methylene dioxy. Aryl is more preferably phenyl, naphthyl or tetrahydronaphthyl, which in each case is either unsubstituted or independently substituted by one or two substituents selected from the group comprising halogen, especially fluorine, chlorine, or bromine; hydroxy; hydroxy etherified by lower alkyl, e.g. by methyl, by halogen-lower alkyl, e.g. trifluoromethyl, or by phenyl; lower alkylene dioxy bound to two adjacent C-atoms, e.g. methylenedioxy, lower alkyl, e.g. methyl or propyl; halogen-lower alkyl, e.g. trifluoromethyl; hydroxy-lower alkyl, e.g. hydroxymethyl or 2-hydroxy-2-propyl; lower alkoxy-lower alkyl; e.g. methoxymethyl or 2-methoxyethyl; lower alkoxycarbonyl-lower alkyl, e.g. methoxy- carbonylmethyl; lower alkynyl, such as 1-propynyl; esterified carboxy, especially lower
alkoxycarbonyl, e.g. methoxycarbonyl, n-propoxy carbonyl or iso-propoxy carbonyl; N-mono- substituted carbamoyl, in particular carbamoyl monosubstituted by lower alkyl, e.g. methyl, n-propyl or iso-propyl; amino; lower alkylamino, e.g. methylamino; di-lower alkylamino, e.g. dimethylamino or diethylamino; lower alkylene-amino, e.g. pyrrolidino or piperidino; lower oxaalkylene-amino, e.g. morpholino, lower azaalkylene-amino, e.g. piperazino, acylamino, e.g. acetylamino or benzoylamino; lower alkylsulfonyl, e.g. methylsulfonyl; sulfamoyl; or phenylsulfonyl.
A cycloalkyl group is preferably cyclopropyl, cyclopentyl, cyclohexyl or cycloheptyl, and may be unsubstituted or substituted by one or more, especially one or two, substitutents selected from the group defined above as substitutents for aryl, most preferably by lower alkyl, such as methyl, lower alkoxy, such as methoxy or ethoxy, or hydroxy, and further by oxo or fused to a benzo ring, such as in benzcyclopentyl or benzcyclohexyl.
Substituted alkyl is alkyl as last defined, especially lower alkyl, preferably methyl; where one or more, especially up to three, substituents may be present, primarily from the group selected from halogen, especially fluorine, amino, N-lower alkylamino, N,N-di-lower alkylamino, N-lower alkanoylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, and phenyl-lower alkoxycarbonyl. Trifluoromethyl is especially preferred.
Mono- or disubstituted amino is especially amino substituted by one or two radicals selected independently of one another from lower alkyl, such as methyl; hydroxy-lower alkyl, such as 2-hydroxyethyl; lower alkoxy lower alkyl, such as methoxy ethyl; phenyl-lower alkyl, such as benzyl or 2-phenylethyl; lower alkanoyl, such as acetyl; benzoyl; substituted benzoyl, wherein the phenyl radical is especially substituted by one or more, preferably one or two, substituents selected from nitro, amino, halogen, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, lower alkanoyl, and carbamoyl; and phenyl-lower alkoxycarbonyl, wherein the phenyl radical is unsubstituted or especially substituted by one or more, preferably one or two, substituents selected from nitro, amino, halogen, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, lower alkanoyl, and carbamoyl; and is preferably N-lower alkylamino, such as N-methylamino, hydroxy-lower alkylamino, such as 2-hydroxyethylamino or 2- hydroxypropyl, lower alkoxy lower alkyl, such as methoxy ethyl, phenyl-lower alkylamino, such as benzylamino, N,N-di-lower alkylamino, N-phenyl-lower alkyl-N-lower alkylamino,
N,N-di-lower alkylphenylamino, lower alkanoylamino, such as acetylamino, or a substituent selected from the group comprising benzoylamino and phenyl-lower alkoxycarbonylamino, wherein the phenyl radical in each case is unsubstituted or especially substituted by nitro or amino, or also by halogen, amino, N-lower alkylamino, N,N-di-lower alkylamino, hydroxy, cyano, carboxy, lower alkoxycarbonyl, lower alkanoyl, carbamoyl or aminocarbonylamino. Disubstituted amino is also lower alkylene-amino, e.g. pyrrolidino, 2-oxopyrrolidino or piperidino; lower oxaalkylene-amino, e.g. morpholino, or lower azaalkylene-amino, e.g. piperazino or N-substituted piperazino, such as N-methylpiperazino or N- methoxycarbonylpiperazino.
Halogen is especially fluorine, chlorine, bromine, or iodine, especially fluorine, chlorine, or bromine.
Etherified hydroxy is especially C8-C2oalkyloxy, such as n-decyloxy, lower alkoxy (preferred), such as methoxy, ethoxy, isopropyloxy, or tert-butyloxy, phenyl-lower alkoxy, such as benzyloxy, phenyloxy, halogen-lower alkoxy, such as trifluoromethoxy, 2,2,2-trifluoroethoxy or 1,1 ,2,2-tetrafluoroethoxy, or lower alkoxy which is substituted by mono- or bicyclic heteroaryl comprising one or two nitrogen atoms, preferably lower alkoxy which is substituted by imidazolyl, such as 1 H-imidazol-1-yl, pyrrolyl, benzimidazolyl, such as 1-benzimidazolyl, pyridyl, especially 2-, 3- or 4-pyridyl, pyrimidinyl, especially 2-pyrimidinyl, pyrazinyl, isoquinolinyl, especially 3-isoquinolinyl, quinolinyl, indolyl or thiazolyl.
Esterified hydroxy is especially lower alkanoyloxy, benzoyloxy, lower alkoxycarbonyloxy, such as tert-butoxycarbonyloxy, or phenyl-lower alkoxycarbonyloxy, such as benzyloxycarbonyloxy.
Esterified carboxy is especially lower alkoxycarbonyl, such as tert-butoxycarbonyl, iso- propoxycarbonyl, methoxycarbonyl or ethoxycarbonyl, phenyl-lower alkoxycarbonyl, or phenyloxycarbonyl.
Alkanoyl is primarily alkylcarbonyl, especially lower alkanoyl, e.g. acetyl.
N-Mono- or N,N-disubstituted carbamoyl is especially substituted by one or two substituents independently selected from lower alkyl, phenyl-lower alkyl and hydroxy-lower alkyl, or lower
alkylene, oxa-lower alkylene or aza-lower alkylene optionally substituted at the terminal nitrogen atom.
A mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted, refers to a heterocyclic moiety that is unsaturated in the ring binding the heteroaryl radical to the rest of the molecule in formula I and is preferably a ring, where in the binding ring, but optionally also in any annealed ring, at least one carbon atom is replaced by a heteroatom selected from the group consisting of nitrogen, oxygen and sulfur; where the binding ring preferably has 5 to 12, more preferably 5 or 6 ring atoms; and which may be unsubstituted or substituted by one or more, especially one or two, substitutents selected from the group defined above as substitutents for aryl, most preferably by lower alkyl, such as methyl, lower alkoxy, such as methoxy or ethoxy, or hydroxy. Preferably the mono- or bicyclic heteroaryl group is selected from 2H-pyrrolyl, pyrrolyl, imidazolyl, benzimidazolyl, pyrazolyl, indazolyl, purinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalyl, quinazolinyl, quinnolinyl, pteridinyl, indolizinyl, 3H-indolyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, furazanyl, benzo[d]pyrazolyl, thienyl and furanyl. More preferably the mono- or bicyclic heteroaryl group is selected from the group consisting of pyrrolyl, imidazolyl, such as 1 H-imidazol-1-yl, benzimidazolyl, such as 1- benzimidazolyl, indazolyl, especially 5-indazolyl, pyridyl, especially 2-, 3- or 4-pyridyl, pyrimidinyl, especially 2-pyrimidinyl, pyrazinyl, isoquinolinyl, especially 3-isoquinolinyl, quinolinyl, especially 4- or 8-quinolinyl, indolyl, especially 3-indolyl, thiazolyl, benzo[d]pyrazolyl, thienyl, and furanyl. In one preferred embodiment of the invention the pyridyl radical is substituted by hydroxy in ortho position to the nitrogen atom and hence exists at least partially in the form of the corresponding tautomer which is pyridin-(1 H)2-one. In another preferred embodiment, the pyrimidinyl radical is substituted by hydroxy both in position 2 and 4 and hence exists in several tautomeric forms, e.g. as pyrimidine-(1H, 3H)2,4-dione.
Heterocyclyl is especially a five, six or seven-membered heterocyclic system with one or two heteroatoms selected from the group comprising nitrogen, oxygen, and sulfur, which may be unsaturated or wholly or partly saturated, and is unsubstituted or substituted especially by lower alkyl, such as methyl, phenyl-lower alkyl, such as benzyl, oxo, or heteroaryl, such as 2-
piperazinyl; heterocyclyl is especially 2- or 3-pyrrolidinyl, 2-oxo-5-pyrrolidinyl, piperidinyl, N- benzyl-4-piperidinyl, N-lower alkyl-4-piperidinyl, N-lower alkyl-piperazinyl, morpholinyl, e.g. 2- or 3-morpholinyl, 2-oxo-1 H-azepin-3-yl, 2-tetrahydrofuranyl, or 2-methyl-1 ,3-dioxolan-2-yl.
Salts are especially the pharmaceutically acceptable salts of compounds of formula I.
Such salts are formed, for example, as acid addition salts, preferably with organic or inorganic acids, from compounds of formula I with a basic nitrogen atom, especially the pharmaceutically acceptable salts. Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid. Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methane- or ethane-sulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1 ,2-disulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 1 ,5- naphthalene-disulfonic acid, 2-, 3- or 4-methylbenzenesulfonic acid, methylsulfuric acid, ethylsulfuric acid, dodecylsulfuric acid, N-cyclohexylsulfamic acid, N-methyl-, N-ethyl- or N- propyl-sulfamic acid, or other organic protonic acids, such as ascorbic acid.
In the presence of negatively charged radicals, such as carboxy or sulfo, salts may also be formed with bases, e.g. metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)amine, or heterocyclic bases, for example N-ethyl- piperidine or N.N'-dimethylpiperazine.
When a basic group and an acid group are present in the same molecule, a compound of formula I may also form internal salts.
VEGFR is vascular endothelial growth factor receptor.
FGFR is fibroblast growth factor receptor.
PDGFR is platelet-derived growth factor receptor.
The invention further relates to the use of COMPOUND or a N-Oxide or a pharmaceutically acceptable salt thereof for the manufacture of medicament having an activity on protein kinases VEGFR-2, Tie-2, c-Src, c-Met, FGFR-1 , Flt-1 , HER-2, c-Abl, c-Raf, PDGFR-beta, c- Kit, or on a combination of the above enzymes, for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation and/or aggregation such as neurodegenerative diseases like Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis.
The invention also relates to a combination of COMPOUND or a pharmaceutically acceptable salt thereof with one or more drugs used for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation such as neurodegenerative diseases like Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis to treat warmblooded animals including mammals, especially humans.
Depending on species, age, individual condition, mode of administration, and the clinical picture in question, effective doses, for example daily doses of about 10-1000 mg, preferably 10-50 mg or 50-200 or 200-400, especially 50-100 or 300-400 mg, are administered to warm-blooded animals of about 70 kg bodyweight. For adult patients with neurological and vascular disorders related to beta-amyloid generation and/or aggregation, especially neurodegenerative diseases like Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis.
The invention relates likewise to a process or a method for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation, especially
neurodegenerative diseases like Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis. The COMPOUNDS or N-oxides thereof can be administered as such or especially in the form of pharmaceutical compositions, prophylactically or therapeutically, preferably in an amount effective against the said diseases, to a warm-blooded animal, for example a human, requiring such treatment. In the case of an individual having a bodyweight of about 70 kg the daily dose administered is from approximately 0.01 g to approximately 5 g, preferably from approximately 0.25 g to approximately 1.5 g, more preferably 0.01 g to 0.05g, even more preferably 0.025g to 0.1 g most preferably 0.05g to 1g of a compound of the present invention.
The invention relates also to a method for administering to a human subject suffering from a neurological and vascular disorders related to beta-amyloid generation and/or aggregation, especially neurodegenerative diseases like Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis, COMPOUND or a pharmaceutically acceptable salt thereof, which comprises administering a pharmaceutically effective amount of COMPOUND or a pharmaceutically acceptable salt thereof to the human subject, preferably once daily for a period exceeding 3 months. The invention relates especially to such method wherein a daily dose of 200 to 800 mg, or 10mg to 200mg especially 400-600 mg or 10-100mg, preferably 400 mg or 10-50mg, of salt is administered.
The invention also relates in a combination which comprises (a) COMPOUND or a pharmaceutically acceptable salt thereof and (b) a therapeutic agent for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation, most preferably a combination wherein the combination partners are present in synergistically effective amounts.
The effective dosage of each of the combination partners employed in the combination may vary depending on a variety of factors including the particular combination of the pharmaceutical compound partners, the route of administration, the severity of the disease, the renal and hepatic functions of the patient. The molar ratio (a)/(b) of the combination
partners is about 0.1 to 10, most preferably 0.3 to 3 and the unit dosage form contains 20 to 200 mg, most preferably 50 to 150 mg of 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide of the formula I.
Example 1 : Cell culture
HEK APPswe cells are plated in microtiter plates precoated with 10 μg/ml poly-D-lysine at 12O00 cells/well in 100 μl/well DMEM medium supplemented with 10% FCS, 0.25 mg/ml G418 sulfate, 1% penicillin streptomycin. The following day, supernatant is replaced with 90 μl/well of fresh medium and 10 μl/well of compound diluted in culture medium are added. Two types of control wells are used: cell culture medium without cells plus 10 μl/well of all compound dilutions (background signals) and cell culture medium from untreated cells (positive control). 24 hours later after compound addition, conditioned medium is collected and Aβ levels determined by a specific sandwich ELISA.
Aβ40and Aβ42 detection by sandwich ELISA
For the sandwich ELISA, the maxisorp microtiterplates are coated overnight at 4°C with 100 μl/well of the monoclonal antibody 25H 10 diluted 1 :1000 in PB for Aβ40 detection or monoclonal antibody B10E7 diluted 1 :2750 for detection of Aβ42. Wells are then emptied, washed three times with 350 μl PBS and blocking is performed for 2 hours at room temperature with 200 μl/well of 2 % BSA, 0.05% Tween20 in PBS. After washing the wells as described above, 10 μl of the conditioned media samples to be tested are added to wells containing 90 μl of medium and 0.18 μg/ml of biotinylated monoclonal β1 antibody and incubated overnight at 4°C. Wells were washed as described above and 100 μl/well of alkaline phosphatase coupled to streptavidin diluted 1 :5'000 in medium are added. After 1 hour incubation at room temperature wells are washed as described above and alkaline phosphatase activity is determined by adding 100 μl/well of diethanolamine buffer, pH 9.8 (100 mM diethanolamine, 1 mM MgCI2, pH adjusted to 9.8 with 2 M HCI) containing the chemiluminescent CSPD substrate (25 mM stock solution diluted 1 :416) and the enhancer Emerald II (diluted 1 :10). After 15 minutes incubation at room temperature in the dark, plates are measured on the luminometer (Analyst AD; LJL Biosystems, USA Aβ 0). Values are given as % reduction of Aβ. The 100% reduction value is calculated from a series of wells containing only medium and extract and the 0% reduction value from conditioned medium
only. Samples are measured in triplicate. A reference compound is included in all plates as control for assay performance.
MTS assay
To determine cytotoxicity, cells are tested by the MTS colohmetric kit performed essentially according to the manufacturer's specifications (Promega, #G5430X). After collecting the conditioned medium for the sandwich ELISA, the rest of the conditioned medium is removed completely and replaced with 100 μl/well culture medium containing one fifth of MTS solution prepared as recommended in the kit. After 3 hours incubation at 37°C, absorbance is read at an OD of 490 nm with a reference wavelength set to 630 nm. Values are given as % metabolic rate (n=6). The 0% value is calculated from wells which had no cells, 100% from wells with an untreated cell layer
Example 2:
4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2- ylamino)-benzamide
This compound has the following activities in cell-free enzyme assays:
VEGFR-2 3.2 microM Tie-2 4.6 microM c-Src 4.6 microM c-Met 4.7 microM FGFR-1 6.7 microM Flt-1 7.7 microM HER-2 7.2 microM c-Abl 295 nM
c-Raf-1 1.1 microM PDGFR-beta 5.8 microM c-Kit 7.8 microM
The compound of example 1 demonstrated a clear reduction of Abeta secretion in the medium of HEK/APPswe cell cultures at concentrations below 10 microM, without having any effect on cellular viability.
Claims
1. Use of an inhibitor of one or more protein kinases VEGFR-2, Tie-2, c-Src, c-Met, FGFR-1 , Flt-1 , HER-2, c-Abl, c-Raf, PDGFR-beta and c-Kit, for the preparation of a medicament for the treatment and/or prevention of neurological and vascular disorders related to beta- amyloid generation and/or aggregation.
2. The use according to claim 1 wherein the inhibitor is a compound of formula I
Ri represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, carboxy- lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl;
R2 represents hydrogen, lower alkyl, optionally substituted by one or more identical or different radicals R3, cycloalkyl, benzcycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted; and R3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amino, mono- or disubstituted amino, cycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted;
or wherein Ri and R2 together represent alkylene with four, five or six carbon atoms optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, oxo, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms; oxaalkylene with one oxygen and three or four carbon atoms; or azaalkylene with one nitrogen and three or four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy-lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N- disubstituted carbamoyl-lower alkyl, cycloalkyl, lower alkoxycarbonyl, carboxy, phenyl, substituted phenyl, pyridinyl, pyrimidinyl, or pyrazinyl;
R4 represents hydrogen, lower alkyl, or halogen; or a pharmaceutically acceptable salt thereof.
3. Use according to claim 1 wherein the inhibitor is a compound selected from,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzanilide,
4-Methyl-Λ/-(3-pyridinyl)-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide,
Λ/-(4-Chlorophenyl)-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide,
2(R)- and 2(S)-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoylamino]propanoic acid,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-/V-(8-quinolinyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(3-[trifluoromethoxy]phenyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyhmidinyl]amino]-/V-(2-pyrrolidinoethyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(3-pyrrolidinophenyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino)-Λ/-(1-[2-pyrimidinyl]-4-piperidinyl)benzamide,
/V-(4-Di-[2-methoxyethyl]amino-3-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
Λ/-(4-[1 H-lmidazolyl]-3-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(2-pyrrolidino-5- trifluoromethylphenyl)benzamide,
Λ/-(3,4-difluorophenyl)-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(3-trifluoromethylbenzyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(3-trifluoromethylphenyl)benzamide,
N-(3-Chloro-5-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
Λ/-(4-Dimethylaminobutyl)-4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide, 4-Methyl-A/-[4-(4-methyl-1-piperazinyl)-3-trifluoromethylphenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[4-(2,2,2-trifluoroethoxy)-3- trifluoromethylphenyljbenzamide,
4-Methyl-Λ -[4-(2-methyl-1 H-imidazolyl)-3-trifluoromethylphenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-/V-(4-phenyl-3-trifluoromethylphenyl)-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-Λ -[4-(4-methyl-1H-imidazolyl)-3-trifluoromethylphenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
Methyl 2(R)- and 2(S)-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoylamio]-3-[4- hydroxyphenyl]propanoate,
Λ/-[2-(Λ/-Cyclohexyl-/V-methylaminomethyl)phenyl]-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
Λ/-[3-[2-(1 H-lmidazolyl)ethoxy]phenyl]-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-Λ/-[3-morpholino-5-trifluoromethylphenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(4-pyrrolidino-3- trifluoromethylphenyl)benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(4-piperidino-3- trifluoromethylphenyl)benzamide,
4-Methyl-Λ/-[4-morpholino-3-trifluoromethylphenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
Λ/-(4-Ethylamino-3-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-(3-trifluoromethoxyphenyl)benzamide,
Λ/-[4-(2-Hydroxypropylamino)-3-trifIuoromethylphenyl]-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
Λ/-(4-Diethylamino-3-trifluoromethylphenyl)-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[3-(3-pyridinyl)-5- trifluorophenyljbenzamide, Λ -[3-[3-(1 H-lmidazolyl)propoxy]phenyl]-4-methyl-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(3-pyridinyl)-3- trifluorophenyljbenzamide,
4-Methyl-Λ/-[3-(4-methyl-1-piperazinyl)-5-trifluorophenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-/v-[3-methylcarbamoyl-5-trifluorophenyl]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide,
4-Methyl-Λ/-[3-methylcarbamoyl-5-morpholino]-3-[[4-(3-pyridinyl)-2- pyrimidinyl]amino]benzamide.
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[3-[3-(1H-imidazol-1-yl)propoxy]- phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[3-[2-(1 H-imidazol-1- yl)ethoxy]phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(ethylamino)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(diethylamino)-3-
(trifluoromethyl)phenyl]benzamide,
(±)-4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-[(2-hydroxypropyl)amino]-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-[bis(2-methoxyethyl)amino]-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(4-methyl-1-piperazinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-tV-[4-(1-piperidinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-V-[4-(1-pyrrolidinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(4-morpholinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-phenyl-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[3-[4-(3-pyridinyl)-3-
(trifluoromethyl)phenyl]methyl]benzamide, 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(1H-imidazol-1-yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ -[4-(2,4-dimethyl-1H-imidazol-1-yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(4-methyl-1 H-imidazol-1-yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[4-(2-methyl-1 H-imidazol-1-yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[3-(4-morpholinyl)-5-
[(methylamino)carbonyl]phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-V-[3-[(methylamino)carbonyl]-5-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyήmidinyl]amino]-Λ/-[5-(3-pyridinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[5-(4-morpholinyl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[5-(2-methyl-1H-imidazol-1-yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2- ylamino)-benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[5-(5-methyl-1H-imidazol-1-yl)-3-
(trifluoromethyl)phenyl]benzamide,
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-/V-[3-(4-methyl-1-piperazinyl)-5-
(trifluoromethyl)phenyl]benzamide, and
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-Λ/-[2-(1-pyrrolidinyl)-5-
(trifluoromethyl)phenyl]benzamide; or a pharmaceutically acceptable salt thereof.
4. Use according to claim 1 wherein the inhibitor is 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide; or a pharmaceutically acceptable salt thereof.
5. Use according to any one of the claims 1-4 wherein a daily dose of 10 to 800 mg of a compound is administered to an adult human.
6. Use according to any one of claims 1 - 5 wherein the disease to be treated is selected from Alzheimer's disease, Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis.
7. Use according to any one of claims 1 - 5 wherein the disease to be treated is Alzheimer's disease.
8. A method of treating mammals suffering from neurological and vascular disorders related to beta-amyloid generation and/or aggregation which comprises administering to a said mammal in need of such treatment a pharmaceutical composition comprising
(a) a dose, effective against neurological and vascular disorders related to beta-amyloid generation and/or aggregation, of 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl- phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide having the formula I
or a pharmaceutically acceptable salt thereof and
(b) a therapeutically effective amount of a second drug selected from drugs used to treat neurological and vascular disorders related to beta-amyloid generation and/or aggregation.
9. Use of an inhibitor according to any one of claims 1 - 4 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation and/or aggregation.
10. A commercial package comprising a compound of formula I
Ri represents hydrogen, lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, carboxy- lower alkyl, lower alkoxycarbonyl-lower alkyl, or phenyl-lower alkyl;
R2 represents hydrogen, lower alkyl, optionally substituted by one or more identical or different radicals R3, cycloalkyl, benzcycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted; and R3 represents hydroxy, lower alkoxy, acyloxy, carboxy, lower alkoxycarbonyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amino, mono- or disubstituted amino, cycloalkyl, heterocyclyl, an aryl group, or a mono- or bicyclic heteroaryl group comprising zero, one, two or three ring nitrogen atoms and zero or one oxygen atom and zero or one sulfur atom, which groups in each case are unsubstituted or mono- or polysubstituted;
or wherein R^ and R2 together represent alkylene with four, five or six carbon atoms optionally mono- or disubstituted by lower alkyl, cycloalkyl, heterocyclyl, phenyl, hydroxy, lower alkoxy, amino, mono- or disubstituted amino, oxo, pyridyl, pyrazinyl or pyrimidinyl; benzalkylene with four or five carbon atoms; oxaalkylene with one oxygen and three or four carbon atoms; or azaalkylene with one nitrogen and three or four carbon atoms wherein nitrogen is unsubstituted or substituted by lower alkyl, phenyl-lower alkyl, lower alkoxycarbonyl-lower alkyl, carboxy-lower alkyl, carbamoyl-lower alkyl, N-mono- or N,N- disubstituted carbamoyl-lower alkyl, cycloalkyl, lower alkoxycarbonyl, carboxy, phenyl, substituted phenyl, pyridinyl, pyrimidinyl, or pyrazinyl;
R represents hydrogen, lower alkyl, or halogen; or a pharmaceutically acceptable salt thereof in the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation, together with instructions for simultaneous, separate or sequential use thereof in the treatment of a proliferative disease.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006536068A JP4827737B2 (en) | 2003-10-27 | 2004-10-26 | Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid-related diseases |
| US10/576,175 US7687512B2 (en) | 2003-10-27 | 2004-10-26 | Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0325031.3 | 2003-10-27 | ||
| GBGB0325031.3A GB0325031D0 (en) | 2003-10-27 | 2003-10-27 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005039586A1 true WO2005039586A1 (en) | 2005-05-06 |
Family
ID=29725439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2004/012080 Ceased WO2005039586A1 (en) | 2003-10-27 | 2004-10-26 | Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7687512B2 (en) |
| JP (1) | JP4827737B2 (en) |
| GB (1) | GB0325031D0 (en) |
| WO (1) | WO2005039586A1 (en) |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006117185A1 (en) * | 2005-05-02 | 2006-11-09 | Novartis Ag | Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome |
| WO2007015870A2 (en) | 2005-07-20 | 2007-02-08 | Novartis Ag | Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| WO2008153959A1 (en) * | 2007-06-07 | 2008-12-18 | Intra-Cellular Therapies, Inc. | Novel heterocycle compounds and uses thereof |
| WO2008153974A1 (en) | 2007-06-07 | 2008-12-18 | Intra-Cellular Therapies, Inc. | Novel heterocycle compounds and uses thereof |
| US7683060B2 (en) | 2006-08-07 | 2010-03-23 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| WO2010060074A1 (en) * | 2008-11-24 | 2010-05-27 | Teva Pharmaceutical Industries Ltd. | Preparation of nilotinib and intermediates thereof |
| US7767675B2 (en) | 2006-11-22 | 2010-08-03 | Incyte Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| WO2011016861A2 (en) | 2009-08-05 | 2011-02-10 | Intra-Cellular Therapies, Inc. | Novel regulatory proteins and inhibitors |
| WO2011162835A1 (en) | 2010-02-03 | 2011-12-29 | Incyte Corporation | Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors |
| CN102316738A (en) * | 2009-02-18 | 2012-01-11 | 盛泰萨路申有限公司 | Amides as kinase inhibitors |
| US8202999B2 (en) | 2005-01-07 | 2012-06-19 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US8227477B2 (en) | 2008-11-05 | 2012-07-24 | Greta Sterimbaum | Nilotinib HCl crystalline forms |
| US8349293B2 (en) | 2007-03-22 | 2013-01-08 | Guerbet | Use of metal nanoparticles in the diagnosis of Alzheimer's disease |
| WO2013014170A1 (en) | 2011-07-27 | 2013-01-31 | Ab Science | Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
| US8420645B2 (en) | 2008-05-21 | 2013-04-16 | Incyte Corporation | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
| US8501760B2 (en) | 2006-09-27 | 2013-08-06 | Novartis Ag | Pharmaceutical compositions comprising nilotinib or its salt |
| US8604045B2 (en) | 2005-12-06 | 2013-12-10 | Novartis Ag | Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis |
| WO2016206551A1 (en) * | 2015-06-24 | 2016-12-29 | 北京键凯科技有限公司 | Application of src protein inhibitor in drug for prevention and/or treatment of alzheimer's disease |
| CN106905298A (en) * | 2015-12-22 | 2017-06-30 | 江苏先声药业有限公司 | The preparation method of hydrochloric acid AMN107 impurity |
| EP4238566A1 (en) * | 2012-05-02 | 2023-09-06 | Georgetown University | Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors |
| US12246009B2 (en) | 2018-11-20 | 2025-03-11 | Georgetown University | Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2404776C2 (en) * | 2005-01-28 | 2010-11-27 | Новартис Аг | APPLICATION OF PYRIMIDYLAMINOBENZAMIDES FOR TREATMENT OF DISEASES SENSITIVE TO MODULATION OF KINASE Tie-2 ACTIVITY |
| EP1976495A2 (en) * | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| MX2009004314A (en) | 2006-11-13 | 2009-05-05 | Pfizer Prod Inc | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof. |
| EP2152079A4 (en) * | 2007-06-04 | 2011-03-09 | Avila Therapeutics Inc | Heterocyclic compounds and uses thereof |
| WO2009036066A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| EP2671891A3 (en) | 2008-06-27 | 2014-03-05 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| EP2315592A1 (en) * | 2008-08-13 | 2011-05-04 | Novartis AG | Treatment of pulmonary arterial hypertension |
| WO2010036813A1 (en) * | 2008-09-24 | 2010-04-01 | University Of South Florida | Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation |
| US8293897B2 (en) | 2008-10-14 | 2012-10-23 | Ning Xi | Compounds comprising a spiro-ring and methods of use |
| CA2752421C (en) * | 2009-03-21 | 2013-08-06 | Ning Xi | Amino ester derivatives, salts thereof and methods of use |
| EP2483406A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
| WO2011118812A1 (en) * | 2010-03-26 | 2011-09-29 | 国立大学法人北海道大学 | Neurodegenerative disease therapeutic agent |
| SI3080103T1 (en) * | 2013-12-11 | 2018-11-30 | Biogen Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| US10538516B2 (en) | 2015-03-25 | 2020-01-21 | National Center For Geriatrics And Gerontology | Oxadiazole derivative and pharmaceutical containing same |
| WO2018148533A1 (en) | 2017-02-09 | 2018-08-16 | Georgetown University | Compositions and methods for treating lysosomal storage disorders |
| US12290516B2 (en) * | 2017-05-12 | 2025-05-06 | The Hong Kong University Of Science And Technology | Heterocyclic compounds as EphA4 inhibitors |
| CN113164478B (en) * | 2018-09-13 | 2024-10-11 | 南加州大学 | Novel FGFR inhibitors and their uses |
| CA3132730A1 (en) * | 2019-03-05 | 2020-09-10 | Hongyi & Associates Llc | Compounds for treating neurodegenerative diseases and cancers |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0588762A1 (en) * | 1992-08-31 | 1994-03-23 | Ciba-Geigy Ag | Use of pyrimidine derivatives as inhibitors of proteinkinase C and antitumor drugs |
| WO2003004488A1 (en) * | 2001-07-03 | 2003-01-16 | Chiron Corporation | Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| WO2003057165A2 (en) * | 2002-01-04 | 2003-07-17 | The Rockefeller University | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS |
| WO2004005281A1 (en) * | 2002-07-05 | 2004-01-15 | Novartis Ag | Inhibitors of tyrosine kinases |
| WO2004029038A1 (en) * | 2002-09-27 | 2004-04-08 | Novartis Ag | Novel pyrimidineamide derivatives and the use thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2983636B2 (en) | 1993-10-01 | 1999-11-29 | ノバルティス アクチェンゲゼルシャフト | Pharmacologically active pyridine derivative and method for producing the same |
-
2003
- 2003-10-27 GB GBGB0325031.3A patent/GB0325031D0/en not_active Ceased
-
2004
- 2004-10-26 JP JP2006536068A patent/JP4827737B2/en not_active Expired - Fee Related
- 2004-10-26 WO PCT/EP2004/012080 patent/WO2005039586A1/en not_active Ceased
- 2004-10-26 US US10/576,175 patent/US7687512B2/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0588762A1 (en) * | 1992-08-31 | 1994-03-23 | Ciba-Geigy Ag | Use of pyrimidine derivatives as inhibitors of proteinkinase C and antitumor drugs |
| WO2003004488A1 (en) * | 2001-07-03 | 2003-01-16 | Chiron Corporation | Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| WO2003057165A2 (en) * | 2002-01-04 | 2003-07-17 | The Rockefeller University | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS |
| WO2004005281A1 (en) * | 2002-07-05 | 2004-01-15 | Novartis Ag | Inhibitors of tyrosine kinases |
| WO2004029038A1 (en) * | 2002-09-27 | 2004-04-08 | Novartis Ag | Novel pyrimidineamide derivatives and the use thereof |
Non-Patent Citations (1)
| Title |
|---|
| ZIMMERMANN J ET AL: "Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 7, no. 2, 21 January 1997 (1997-01-21), pages 187 - 192, XP004135990, ISSN: 0960-894X * |
Cited By (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8592486B2 (en) | 2005-01-07 | 2013-11-26 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US8202999B2 (en) | 2005-01-07 | 2012-06-19 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US7666874B2 (en) | 2005-05-02 | 2010-02-23 | Novartis Ag | Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome |
| WO2006117185A1 (en) * | 2005-05-02 | 2006-11-09 | Novartis Ag | Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome |
| EP2266572A1 (en) * | 2005-05-02 | 2010-12-29 | Novartis AG | Use of pyrimidylaminobenzamide derivatives for the treatment of hypereosinophilic syndrome |
| AU2006243395B2 (en) * | 2005-05-02 | 2010-03-11 | Novartis Ag | Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome |
| AU2012201453C1 (en) * | 2005-07-20 | 2024-05-23 | Novartis Ag | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| TWI406661B (en) * | 2005-07-20 | 2013-09-01 | Novartis Ag | Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| NO341930B1 (en) * | 2005-07-20 | 2018-02-19 | Novartis Ag | Crystalline forms of 4-methyl-N- [3- (4-methylimidazol-1-yl) -5-trifluoromethylphenyl] -3- (4-pyridin-3-ylpyrimidin-2-ylamino) benzamide |
| EA013464B1 (en) * | 2005-07-20 | 2010-04-30 | Новартис Аг | Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-2-ylamino)-benzamide |
| KR101651288B1 (en) | 2005-07-20 | 2016-08-25 | 노파르티스 아게 | Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| EP2535337A1 (en) * | 2005-07-20 | 2012-12-19 | Novartis AG | Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide sulfate and its amorphous form |
| US8829015B2 (en) | 2005-07-20 | 2014-09-09 | Novartis Ag | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| US8415363B2 (en) | 2005-07-20 | 2013-04-09 | Novartis Ag | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| EP2284167A3 (en) * | 2005-07-20 | 2011-03-02 | Novartis AG | crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| WO2007015870A2 (en) | 2005-07-20 | 2007-02-08 | Novartis Ag | Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| EP2284168A3 (en) * | 2005-07-20 | 2011-04-13 | Novartis AG | Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| AU2012201453B2 (en) * | 2005-07-20 | 2013-09-05 | Novartis Ag | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| KR20080027853A (en) * | 2005-07-20 | 2008-03-28 | 노파르티스 아게 | 4-methyl-N- [3- (4-methyl-imidazol-1-yl) -5-trifluoromethylphenyl] -3- (4-pyridin-3-yl-pyrimidin-2-ylamino) benz Crystalline form of amide |
| US8343984B2 (en) | 2005-07-20 | 2013-01-01 | Novartis Ag | Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| WO2007015870A3 (en) * | 2005-07-20 | 2007-06-07 | Novartis Ag | Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| EP2543665A3 (en) * | 2005-07-20 | 2013-05-29 | Novartis AG | Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base |
| EA016856B1 (en) * | 2005-07-20 | 2012-08-30 | Новартис Аг | Crystalline forms of 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamide |
| US8604045B2 (en) | 2005-12-06 | 2013-12-10 | Novartis Ag | Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis |
| JP2015091818A (en) * | 2005-12-06 | 2015-05-14 | ノバルティス アーゲー | Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis |
| US8143251B2 (en) | 2006-08-07 | 2012-03-27 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| US7915408B2 (en) | 2006-08-07 | 2011-03-29 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| US7683060B2 (en) | 2006-08-07 | 2010-03-23 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| US8501760B2 (en) | 2006-09-27 | 2013-08-06 | Novartis Ag | Pharmaceutical compositions comprising nilotinib or its salt |
| EP2068839B1 (en) | 2006-09-27 | 2015-09-23 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
| US12084449B2 (en) | 2006-11-22 | 2024-09-10 | Incyte Holdings Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| US10738052B2 (en) | 2006-11-22 | 2020-08-11 | Incyte Holdings Corporation | Imidazotriaines and imidazopyrimidines as kinase inhibitors |
| US8461330B2 (en) | 2006-11-22 | 2013-06-11 | Incyte Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| US7767675B2 (en) | 2006-11-22 | 2010-08-03 | Incyte Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| US9944645B2 (en) | 2006-11-22 | 2018-04-17 | Incyte Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| US11261191B2 (en) | 2006-11-22 | 2022-03-01 | Incyte Holdings Corporation | Imidazotriaines and imidazopyrimidines as kinase inhibitors |
| EP3034075A1 (en) | 2006-11-22 | 2016-06-22 | Incyte Holdings Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| EP3443958A1 (en) | 2006-11-22 | 2019-02-20 | Incyte Holdings Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| EP2497470A1 (en) | 2006-11-22 | 2012-09-12 | Incyte Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| US8349293B2 (en) | 2007-03-22 | 2013-01-08 | Guerbet | Use of metal nanoparticles in the diagnosis of Alzheimer's disease |
| US8367686B2 (en) | 2007-06-07 | 2013-02-05 | Intra-Cellular Therapies, Inc. | Heterocycle compounds and uses thereof |
| WO2008153959A1 (en) * | 2007-06-07 | 2008-12-18 | Intra-Cellular Therapies, Inc. | Novel heterocycle compounds and uses thereof |
| WO2008153974A1 (en) | 2007-06-07 | 2008-12-18 | Intra-Cellular Therapies, Inc. | Novel heterocycle compounds and uses thereof |
| US9056837B2 (en) | 2007-06-07 | 2015-06-16 | Intra-Cellular Therapies, Inc. | Heterocycle compounds and uses thereof |
| US9062023B2 (en) | 2007-06-07 | 2015-06-23 | Intra-Cellular Therapies, Inc. | Heterocycle compounds and uses thereof |
| US11452726B2 (en) | 2008-05-21 | 2022-09-27 | Incyte Corporation | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
| US8901123B2 (en) | 2008-05-21 | 2014-12-02 | Incyte Corporation | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
| US10799509B2 (en) | 2008-05-21 | 2020-10-13 | Incyte Corporation | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
| US12427154B2 (en) | 2008-05-21 | 2025-09-30 | Incyte Holdings Corporation | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
| US10245265B2 (en) | 2008-05-21 | 2019-04-02 | Incyte Incorporation | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
| US8420645B2 (en) | 2008-05-21 | 2013-04-16 | Incyte Corporation | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
| EP3287449A2 (en) | 2008-05-21 | 2018-02-28 | Incyte Holdings Corporation | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
| US8592442B2 (en) | 2008-11-05 | 2013-11-26 | Teva Pharmaceutical Industries Ltd. | Nilotinib HCl crystalline forms |
| US8227477B2 (en) | 2008-11-05 | 2012-07-24 | Greta Sterimbaum | Nilotinib HCl crystalline forms |
| WO2010060074A1 (en) * | 2008-11-24 | 2010-05-27 | Teva Pharmaceutical Industries Ltd. | Preparation of nilotinib and intermediates thereof |
| CN102316738A (en) * | 2009-02-18 | 2012-01-11 | 盛泰萨路申有限公司 | Amides as kinase inhibitors |
| US9605041B2 (en) | 2009-08-05 | 2017-03-28 | Intra-Cellular Therapies, Inc. | Regulatory proteins and inhibitors |
| WO2011016861A2 (en) | 2009-08-05 | 2011-02-10 | Intra-Cellular Therapies, Inc. | Novel regulatory proteins and inhibitors |
| US10919901B2 (en) | 2010-02-03 | 2021-02-16 | Incyte Holdings Corporation | Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors |
| US10472367B2 (en) | 2010-02-03 | 2019-11-12 | Incyte Incorporation | Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors |
| US9221824B2 (en) | 2010-02-03 | 2015-12-29 | Incyte Holdings Corporation | Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors |
| US9988387B2 (en) | 2010-02-03 | 2018-06-05 | Incyte Holdings Corporation | Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors |
| US8487096B2 (en) | 2010-02-03 | 2013-07-16 | Incyte Corporation | Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors |
| WO2011162835A1 (en) | 2010-02-03 | 2011-12-29 | Incyte Corporation | Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors |
| US9168245B2 (en) | 2011-07-27 | 2015-10-27 | Ab Science | Selective protein kinase inhibitors |
| WO2013014170A1 (en) | 2011-07-27 | 2013-01-31 | Ab Science | Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
| EP4238566A1 (en) * | 2012-05-02 | 2023-09-06 | Georgetown University | Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors |
| WO2016206551A1 (en) * | 2015-06-24 | 2016-12-29 | 北京键凯科技有限公司 | Application of src protein inhibitor in drug for prevention and/or treatment of alzheimer's disease |
| CN106905298A (en) * | 2015-12-22 | 2017-06-30 | 江苏先声药业有限公司 | The preparation method of hydrochloric acid AMN107 impurity |
| US12246009B2 (en) | 2018-11-20 | 2025-03-11 | Georgetown University | Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007509106A (en) | 2007-04-12 |
| GB0325031D0 (en) | 2003-12-03 |
| US7687512B2 (en) | 2010-03-30 |
| JP4827737B2 (en) | 2011-11-30 |
| US20070129389A1 (en) | 2007-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7687512B2 (en) | Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders | |
| US20130040972A1 (en) | USE OF c-Src INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA | |
| US8604045B2 (en) | Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis | |
| AU2016216636A1 (en) | Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity | |
| RU2481840C2 (en) | COMBINATION, INCLUDING A) PYRIMIDYLAMINOBENZAMIDE AND B) KINASE Thr315lle INHIBITOR | |
| US20080255171A1 (en) | Combination of Nilotinib with Farnesyl Transferase Inhibitors | |
| EP1843771B1 (en) | Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity | |
| WO2007051862A1 (en) | Combination of organic compounds | |
| AU2011202950B2 (en) | Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia | |
| EP2186514B1 (en) | Treatment of Malignant Peripheral Nerve Sheath Tumors | |
| AU2011202833B2 (en) | Combination comprising a) a pyrimidylaminobenzamide compound, and b) a Thr315lle kinase inhibitor | |
| CN101484172A (en) | Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315ile kinase inhibitor | |
| AU2013201915A1 (en) | Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2007129389 Country of ref document: US Ref document number: 10576175 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006536068 Country of ref document: JP |
|
| 122 | Ep: pct application non-entry in european phase | ||
| WWP | Wipo information: published in national office |
Ref document number: 10576175 Country of ref document: US |